Biora Therapeutics, Inc. (BIOR)
USD 0.22
(0.0%)
USD 0.22
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 31.21 Million USD | -41.68% |
| 2022 | 53.52 Million USD | -50.82% |
| 2021 | 108.83 Million USD | -29.53% |
| 2020 | 154.44 Million USD | 51.82% |
| 2019 | 101.72 Million USD | -12.6% |
| 2018 | 116.39 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 18.26 Million USD | -20.56% |
| 2024 Q1 | 22.99 Million USD | -26.35% |
| 2023 Q2 | 49.67 Million USD | -6.71% |
| 2023 FY | 31.21 Million USD | -41.68% |
| 2023 Q4 | 31.21 Million USD | -10.05% |
| 2023 Q3 | 34.7 Million USD | -30.14% |
| 2023 Q1 | 53.24 Million USD | -0.53% |
| 2022 Q3 | 62.61 Million USD | -18.79% |
| 2022 Q2 | 77.1 Million USD | -11.11% |
| 2022 Q1 | 86.73 Million USD | -20.31% |
| 2022 FY | 53.52 Million USD | -50.82% |
| 2022 Q4 | 53.52 Million USD | -14.52% |
| 2021 Q2 | 119.94 Million USD | -6.71% |
| 2021 Q1 | 128.57 Million USD | -16.75% |
| 2021 FY | 108.83 Million USD | -29.53% |
| 2021 Q3 | 97.68 Million USD | -18.56% |
| 2021 Q4 | 108.83 Million USD | 11.42% |
| 2020 Q3 | 119.61 Million USD | -35.83% |
| 2020 Q4 | 154.44 Million USD | 29.11% |
| 2020 Q2 | 186.41 Million USD | 68.02% |
| 2020 Q1 | 110.95 Million USD | 9.07% |
| 2020 FY | 154.44 Million USD | 51.82% |
| 2019 FY | 101.72 Million USD | -12.6% |
| 2019 Q3 | 96.1 Million USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q4 | 101.72 Million USD | 5.85% |
| 2018 FY | 116.39 Million USD | 0.0% |
| 2018 Q4 | 116.39 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -10335.297% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -444.195% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -112.419% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -869.41% |
| Better Therapeutics, Inc. | 22.94 Million USD | -36.055% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -8.854% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -737.512% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -51.942% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -47.777% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 51.56% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -1226.204% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 56.033% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -19.41% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -40976.152% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -156.512% |
| Molecular Templates, Inc. | 35.38 Million USD | 11.78% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -614.04% |
| NexImmune, Inc. | 8.59 Million USD | -263.221% |
| Orgenesis Inc. | 14.55 Million USD | -114.507% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -164.489% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -24943.524% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -449.521% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -7857.631% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 93.398% |
| Statera Biopharma, Inc. | 21.16 Million USD | -47.451% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -208.906% |
| Trevena, Inc. | 40.6 Million USD | 23.125% |
| Vaxxinity, Inc. | 44.35 Million USD | 29.621% |
| Vaccinex, Inc. | 3.63 Million USD | -759.681% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -78614.444% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 44.939% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -5517.088% |